Company: GLPG
Filing Date: 2025-03-27
Form Type: 20-F
Source: 0001558370-25-003806
Chunk: 452

Company: GALAPAGOS NV
Filing Date: 2025-03-27
Form: 20-F
Item: Item 19
Chunk 452
---
 in revenue €10.6 million of royalties from Gilead on filgotinib. The royalties on sales of Jyseleca® performed by Gilead in Japan were not reported as discontinued operations as we still have the right to receive those royalties on future sales made by Gilead and its commercialization partners (this right is not subject to transfer to Alfasigma as part of the transfer of the Jyseleca® business to them).​
​
Collaboration with Gilead 
​
We refer to note 2 of these consolidated financial statements for a general description of our collaboration with Gilead. ​
In addition, we concluded as follows for the remaining performance obligations:​
Access rights to the drug discovery platform, option rights and R&D activities ●The revenue allocated to the drug discovery platform will be recognized over time as Gilead receives exclusive access to our drug discovery platform and option rights on our current and future pipeline as well as R&D activities during the collaboration term. Management concluded that an equal spread over the collaboration period is the most reliable and appropriate recognition method. ●At inception of the collaboration (July 2019) we assessed the appropriate period over which to recognize the drug discovery platform revenue to be 10 years. This is because we granted exclusive rights over a 10-year period. However, if at the end of the 10-year period, some programs in existence as of this time would 

F-35

have reached the clinic (i.e., IND filed with regulatory authorities), the rights for those specific programs may have been extended, for a maximum of three years. This is reassessed at each year-end based on the evolution of our pipeline and is still valid per December 31, 2024.

8.      Operating costs and other operating income
RESEARCH AND DEVELOPMENT EXPENSES
The following table summarizes research and development expenses for the years ended December 31, 2024, 2023 and 2022.​

                     ​                        ​   ​        ​       ​    ​        ​       ​    ​        ​    
------------------------------------------------------------------------------------------------------------
​                                             ​   Year ended December 31,                                   
​                                             2024                 2023                  2022               
​                                             ​   ​                                     (Euro, in thousands)
Personnel costs                               ​   €     (87,740)   ​    €     (95,788)   ​    €    (115,484)
Subcontracting                                ​